What Is Pleiotrophin? Definition and What Research Reports

Definition

Pleiotrophin (abbreviated PTN, and historically called heparin-binding growth-associated molecule or HB-GAM) is a small, highly basic secreted protein classified as a heparin-binding growth factor. Reviews of its biology described pleiotrophin as an 18 kDa cytokine-like factor that is developmentally regulated, expressed strongly in the nervous system and skeletal tissue during development, and re-expressed in adult tissues during injury, inflammation and tumour growth, where it signals through receptors including protein tyrosine phosphatase receptor type Z (PTPRZ1), anaplastic lymphoma kinase (ALK), syndecans and integrins (PMID 32564788). In short: pleiotrophin is a naturally occurring growth factor, not a synthetic peptide analogue, and it is studied as an endogenous signalling molecule rather than as a marketed drug.

What class of molecule is it, and where does it come from?

Pleiotrophin belongs to the small family of heparin-binding growth factors that also includes midkine. It is encoded by the PTN gene, secreted into the extracellular space, and held in place by binding to glycosaminoglycans such as heparin and chondroitin sulfate in the extracellular matrix. Work characterising this interaction used synthetic glycosaminoglycan mimetics and reported that pleiotrophin binding depended on the sulfation pattern and chain features of the glycan, consistent with matrix glycosaminoglycans acting as co-receptors that concentrate the protein near its cell-surface targets (PMID 35631323).

In terms of cellular source, much of the recent literature has focused on astrocytes. A 2025 study reported that astrocytes in the prefrontal cortex were a major source of pleiotrophin in that brain region and that astrocyte-specific deficiency of pleiotrophin contributed to stress-induced depressive-like responses in male mice (PMID 40087317). Other work reported astrocyte-derived pleiotrophin in the context of central nervous system autoimmune inflammation (PMID 35046956). Outside the brain, published research has described pleiotrophin expression in endothelium, adipose tissue and prostate tissue, discussed below.

How the term is used in peptide and growth-factor research

In laboratory literature, "pleiotrophin" is used in three broad ways:

• As an endogenous signalling protein whose loss or overexpression is manipulated genetically (knockout mice, conditional astrocyte deletion) to test what it does.
• As a recombinant protein applied to cells or tissues in vitro to probe receptor pathways such as PTPRZ1, ALK and neuropilin-1.
• As a measurable biomarker in human blood or tissue, correlated with a clinical variable.

Because it is a full-length protein rather than a short synthetic sequence, pleiotrophin sits at the edge of what is usually called "peptide research". It appears in peptide glossaries mainly because it is a heparin-binding factor that interacts with glycosaminoglycan mimetics and because fragments and receptor-binding regions of pleiotrophin have been studied as tools. This page is definitional: it describes what researchers reported, not what anyone should do.

What the Published Literature Reports

Nervous system and glia

A 2017 study examined pleiotrophin in neuroinflammation and reported that it regulated microglia-mediated inflammatory responses, linking the growth factor to glial activation states (PMID 28259175). In an experimental model of autoimmune central nervous system inflammation, researchers reported that astrocyte-derived pleiotrophin mitigated late-stage disease, indicating a context-dependent role in limiting chronic inflammation (PMID 35046956). A 2025 study in Down syndrome models reported that dysregulation of astrocyte-secreted pleiotrophin contributed to neuronal structural and functional deficits (PMID 40971297). Taken together, the study reports place pleiotrophin at the astrocyte–neuron and astrocyte–microglia interface.

Blood vessels and angiogenesis

Pleiotrophin has been described as an angiogenic factor. In mouse models of ocular vascular disease, researchers reported a pathogenic role for pleiotrophin in abnormal retinal vessel growth and discussed its therapeutic potential as a target (PMID 28447229). Separate work analysed the endothelialisation potential of pleiotrophin, examining how the factor influenced endothelial cell behaviour relevant to vascular surface coverage (PMID 30660899). In humans, a clinical association study reported that pleiotrophin levels were associated with improved coronary collateral circulation (PMID 28885394). These are observational and model findings, not evidence of a therapy.

Cancer cell behaviour

A 2015 study reported that pleiotrophin exerted its migration and invasion effects through the neuropilin-1 pathway, identifying neuropilin-1 as a mediator of pleiotrophin-driven cell motility (PMID 26408254). Reviews of pleiotrophin activity and mechanism similarly discussed its re-expression in tumour settings and its signalling through receptor tyrosine phosphatase and kinase pathways (PMID 32564788).

Metabolism and peripheral tissue

A 2021 study in mice reported that pleiotrophin deficiency induced browning of periovarian adipose tissue and protected against high-fat diet-induced hepatic steatosis, implicating the factor in adipose phenotype and liver fat accumulation (PMID 34502170). A 2025 translational study reported that pleiotrophin modulated cell proliferation, prostate smooth muscle contraction and fibrosis in hyperplastic prostate tissue (PMID 41107820).

Reported Roles at a Glance

Safety and Adverse Events: What Studies Report

The verified literature summarised here consists of mechanistic cell studies, genetic mouse models and human association data; it does not include trials administering pleiotrophin to people, and no adverse-event profile, dose range or human safety dataset is reported in these papers. Notably, some of the findings point in opposing directions depending on tissue: researchers reported a pathogenic contribution in ocular neovascular models (PMID 28447229) and a role in tumour cell migration and invasion via neuropilin-1 (PMID 26408254), while other work reported protective or restorative roles in CNS inflammation (PMID 35046956). That context-dependence is itself a key finding in the mechanism literature (PMID 32564788).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or any compound discussed in the research literature. Pleiotrophin is described here as a subject of published research, and nothing on this page describes a therapy, a protocol or a product.

Related Terms

• Midkine — the other member of the heparin-binding growth factor family that includes pleiotrophin, discussed alongside it in mechanism reviews (PMID 32564788).
• PTPRZ1 — a receptor protein tyrosine phosphatase described as a pleiotrophin receptor (PMID 32564788).
• Neuropilin-1 — a co-receptor reported to mediate pleiotrophin-driven migration and invasion (PMID 26408254).
• Glycosaminoglycans — matrix sugars that bind pleiotrophin in a sulfation-dependent manner (PMID 35631323).

References

• Pleiotrophin: Activity and mechanism (Advances in Clinical Chemistry, 2020)
• Pleiotrophin Interaction with Synthetic Glycosaminoglycan Mimetics (Pharmaceuticals, 2022)
• Astrocytic pleiotrophin deficiency in the prefrontal cortex contributes to stress-induced depressive-like responses in male mice (Nature Communications, 2025)
• Pleiotrophin regulates microglia-mediated neuroinflammation (Journal of Neuroinflammation, 2017)
• Astrocyte-Derived Pleiotrophin Mitigates Late-Stage Autoimmune CNS Inflammation (Frontiers in Immunology, 2021)
• Dysregulation of astrocyte-secreted pleiotrophin contributes to neuronal structural and functional deficits in Down syndrome (Cell Reports, 2025)
• Pathogenic role and therapeutic potential of pleiotrophin in mouse models of ocular vascular disease (Angiogenesis, 2017)
• Pleiotrophin: Analysis of the endothelialisation potential (Advances in Medical Sciences, 2019)
• Pleiotrophin levels are associated with improved coronary collateral circulation (Coronary Artery Disease, 2018)
• Pleiotrophin exerts its migration and invasion effect through the neuropilin-1 pathway (Neoplasia, 2015)
• Pleiotrophin Deficiency Induces Browning of Periovarian Adipose Tissue and Protects against High-Fat Diet-Induced Hepatic Steatosis (International Journal of Molecular Sciences, 2021)
• Pleiotrophin modulates cell proliferation, prostate smooth muscle contraction and fibrosis in hyperplastic prostate (Journal of Translational Medicine, 2025)